How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Want to cut your energy bills? Here’s how five experts are doing it 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CAMBRIDGE, Mass., May 30, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today announced that it is scheduled to present at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 13 at 10:40 a.m. PT (1:40 p.m. ET). Edward Kaye, Sarepta’s chief executive officer, will be the presenter at the fireside chat.
The presentation will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
